In 2019 Acorai was founded and set out to develop the first scalable and non-invasive intracardiac pressure monitor in the world.
Acorai believe that it has the potential to dramatically improve the health outcome for more than 60 million people suffering from heart failure around the world.
We are happy to announce LSI Epsilons sixth investment VoxlBio. VoxlBio are empowering discoveries through advanced genetic spatial analysis. Tools that change how we can understand and diagnose komplex diseases as cancer. We are looking forward to the journey...
Video on Youtube: here. Spotify: here.
LSI portfolio company Acorai, a Swedish developer and manufacturer of innovative devices for heart failure management, announced the closing of a $4.5M investment from the EIC Fund, Taiwan Medical University, and private investors. The capital will be used to complete...